Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 640pembrolizumab 570Magnetic Resonance Spectroscopy 550Carboplatin 430Cyclophosphamide 382Cisplatin 376Biopsy 364Paclitaxel 312Nivolumab 310Gemcitabine 302Radiotherapy 275Bevacizumab 243Dexamethasone 213fludarabine 209Docetaxel 193durvalumab 182atezolizumab 179Oxaliplatin 173Rituximab 168Fluorouracil 168venetoclax 167Pemetrexed 165Doxorubicin 163Radiation 161Capecitabine 161Radiosurgery 149Etoposide 138Ipilimumab 136Leucovorin 134Lenalidomide 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurokinin-1 Receptor Antagonists × 90 days × Clear all
NCT06780085 2026-05-26

MK-3475-01H

Merck Sharp & Dohme LLC

Phase 2 Recruiting
96 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡